Hemoptysis (> teaspoon [. mL] of bright red blood) within months prior to randomization Severe, active co-morbidity defined as follows:\r\n* Current (within days of cycle , day ) signs and/or symptoms of bowel obstruction\r\n* Patients who require parental hydration and/or nutrition\r\n* Patients who require drainage gastrostomy tube\r\n* Evidence of bleeding diathesis or clinically significant coagulopathy\r\n* Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\r\n* History of hemoptysis (>= / teaspoon of bright red blood per episode) within month of study enrollment History of hemorrhage or hemoptysis (> teaspoon bright red blood) within months of starting study treatment Active hemoptysis (bright red blood of at least . teaspoon) within weeks prior to the first dose of study drug Pulmonary hemorrhage or gross hemoptysis (bright red blood of >= / teaspoon per episode) within months prior to enrollment History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day Patients with history of hematemesis or hemoptysis (defined as having bright red blood of / teaspoon or more per episode) within days prior to registration History of pulmonary hemorrhage/hemoptysis >= grade (defined as >= . mL bright red blood per episode) within month prior to randomization. History of hemorrhage or hemoptysis (> teaspoon bright red blood) within months prior to study treatment (Bevacizumab-related exclusion) History of hemoptysis (>= / teaspoon of bright red blood per episode) within month of study enrollment for any tumor type History of hemoptysis (>= / teaspoon of bright red blood per episode) within month of study enrollment History of hemoptysis (>= / teaspoon of bright red blood per episode) =< days of study enrollment History of hemoptysis (defined as > / tablespoon [tsp] of bright red blood per day) Patients with hemoptysis (defined as bright red blood or >= / teaspoon) within months prior to enrollment, or with central or cavitating lesions, will be excluded History of pulmonary hemorrhage/hemoptysis >= grade (defined as >= . mL bright red blood per episode) within month prior to on-study date Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within weeks prior to the first dose of study drug. History of hemorrhage or hemoptysis (> / teaspoon bright red blood) within months of starting study treatment History of hemoptysis ( >= / teaspoon of bright red blood per episode) within month prior to day History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day of FOLFIRI + bevacizumab initiation Active hemoptysis (bright red blood of at least . teaspoon) or tumor bleeding within weeks prior to the first dose of study drug History of hemoptysis (? / teaspoon of bright red blood per episode) within month prior to Day Bleeding diathesis including clinically significant platelet disorders or active hemoptysis (defined as bright red blood of ? / teaspoon [. mL] in any hour period) within months prior to study day . For clinically significant epistaxis within weeks prior to study day , no risk of further bleeding must be clearly documented. History of hemorrhage or hemoptysis (> teaspoon bright red blood) within months of starting study treatment No active or recent hemoptysis (>= / teaspoon of bright red blood per episode) =< days prior to registration Patients are excluded if they have a history of hemoptysis (bright red blood of / teaspoon or more per episode) within months prior to randomization History of hemorrhage or hemoptysis (> teaspoon bright red blood) within months of starting study treatment History of hemoptysis (>= / teaspoon of bright red blood per episode) within month of study enrollment for any tumor type Active hemoptysis (bright red blood of at least . mL ie, half teaspoon) within weeks prior to the first dose of study drug. History of hemoptysis (>= / teaspoon of bright red blood per episode) or other significant spontaneous bleeding event within month prior to day of study drug or at any time on a prior VEGF inhibitor Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least . teaspoon) within days prior to randomization Have a significant bleeding disorder or vasculitis or had a Grade ? bleeding episode within weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ?/ teaspoon) within months prior to enrollment are excluded. Active or recent history of hemoptysis (>= / teaspoon of bright red blood per episode) =< days prior to registration/randomization Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within days prior to enrollment Active hemoptysis (bright red blood of at least . teaspoon) within weeks before the first dose of study drug. History of hemoptysis (/ teaspoon of bright red blood per episode) within month prior to Day . No history of gross hemoptysis (defined as bright red blood of a half-teaspoon or more) within months prior to enrollment History of hemoptysis >= grade (defined as bright red blood of at least . mL) =< months prior to randomization History of gastrointestinal (GI) bleeding (hemoptysis/melena/hematochezia, >= / teaspoon of bright red blood per episode) within month prior to day History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day - History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day History of uncontrolled hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day History of hemoptysis (greater than or equal to / teaspoon of bright red blood per episode) within month prior to day History of hemoptysis ( >= / teaspoon of bright red blood per episode) within month prior to Day History of hemoptysis (>/=/ teaspoon of bright red blood per episode) within month prior to Day . History of/or current evidence of hemoptysis (bright red blood of teaspoon or more) History of hemoptysis (? / teaspoon of bright red blood per episode) within month prior to Day Patients with a history of gross hemoptysis (defined as bright red blood of teaspoon or more) will be excluded from this trial History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to Day History of hemoptysis (>= teaspoon of bright red blood per episode) within month prior to day History of hemoptysis (>= / teaspoon of bright red blood per episode) within month prior to day Active hemoptysis (bright red blood > teaspoon on more than one occasion) =< weeks prior to registration Active hemoptysis (bright red blood of at least . teaspoon) within weeks prior to the first dose of study drug.